Point72 Asset Management L.P. Has $37.26 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Point72 Asset Management L.P. lifted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 32.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,437,073 shares of the company’s stock after buying an additional 603,222 shares during the quarter. Point72 Asset Management L.P. owned about 2.66% of Arcus Biosciences worth $37,263,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Louisiana State Employees Retirement System grew its position in Arcus Biosciences by 2.6% during the second quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock worth $419,000 after buying an additional 700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Arcus Biosciences by 2.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock worth $471,000 after purchasing an additional 843 shares in the last quarter. Diversified Trust Co increased its position in shares of Arcus Biosciences by 12.1% in the second quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after purchasing an additional 1,467 shares during the period. WINTON GROUP Ltd raised its stake in Arcus Biosciences by 3.3% in the second quarter. WINTON GROUP Ltd now owns 59,137 shares of the company’s stock valued at $901,000 after purchasing an additional 1,872 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Arcus Biosciences by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 34,764 shares of the company’s stock worth $657,000 after purchasing an additional 1,906 shares during the period. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Up 0.1 %

Shares of NYSE:RCUS opened at $17.11 on Friday. Arcus Biosciences, Inc. has a 52-week low of $13.52 and a 52-week high of $20.31. The company has a market capitalization of $1.57 billion, a PE ratio of -5.43 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The company has a fifty day moving average of $16.30 and a 200-day moving average of $16.01.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. The firm had revenue of $48.00 million during the quarter, compared to the consensus estimate of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business’s quarterly revenue was up 50.0% on a year-over-year basis. During the same period last year, the company earned ($0.94) earnings per share. On average, equities analysts predict that Arcus Biosciences, Inc. will post -3.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on RCUS shares. Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 target price for the company. HC Wainwright restated a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Barclays lifted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Arcus Biosciences currently has a consensus rating of “Buy” and a consensus target price of $34.00.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.